LSL Pharma Group Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '21 Jul 31, 2021
Revenue	28.74	17.75	10.03	8.21	-
Revenue Growth (YoY)	61.96%	76.98%	22.08%	-	-
Cost of Revenue	23.64	12.4	8.38	10.39	-
Gross Profit	5.1	5.35	1.65	-2.17	-
Selling, General & Admin	7.23	4.52	3.64	3.92	-
Research & Development	-	-	-	0.67	-
Other Operating Expenses	0.18	0.42	4.67	0.43	0.06
Total Operating Expenses	7.41	4.94	8.31	5.01	0.06
Operating Income	-2.13	0.82	-2	-13.94	-0.06
Interest Expense	-3	-1.9	-1.81	-0.88	-3.1
Other Non-Operating Income (Expense)	2.43	4.86	-	-	-
Total Non-Operating Income (Expense)	-0.58	2.96	-1.81	-0.88	-3.1
Pretax Income	-2.89	3.37	-8.47	-8.06	-3.16
Provision for Income Taxes	-0.07	0.05	-	-	-
Net Income	-2.82	3.32	-8.47	-8.06	0.09
Net Income to Common	-2.82	3.32	-8.47	-8.06	0.09
Shares Outstanding (Basic)	118	105	80	67	21
Shares Outstanding (Diluted)	118	105	80	67	21
Shares Change (YoY)	11.58%	31.13%	19.66%	225.40%	-
EPS (Basic)	-0.02	0.03	-0.11	-0.12	0.00
EPS (Diluted)	-0.02	0.03	-0.11	-0.12	0.00
Shares Outstanding	117.62	105.41	82.43	68.09	20.65
Free Cash Flow	-4.46	-4.77	-7.73	-4.16	0
Free Cash Flow Per Share	-0.04	-0.05	-0.10	-0.06	-
Gross Margin	17.75%	30.13%	16.40%	-26.44%	-
Operating Margin	-7.41%	4.64%	-19.93%	-169.70%	-
Profit Margin	-9.81%	18.69%	-84.48%	-98.15%	-
FCF Margin	-15.53%	-26.89%	-77.04%	-50.66%	-
EBITDA	0.4	2.33	-0.87	-12.89	-0.06
EBITDA Margin	1.40%	13.15%	-8.68%	-156.95%	-
EBIT	-2.13	0.82	-2	-13.94	-0.06
EBIT Margin	-7.41%	4.64%	-19.93%	-169.70%	-
Effective Tax Rate	2.25%	1.49%	0.00%	0.00%	0.00%

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.